NeoImmuneTech, a Kosdaq-listed biotech firm, said on Tuesday it would provide its cancer immunotherapy candidate NT-17 to Imugene, an Australian immuno-oncology company, to conduct a study combining NT-I7 with the latter’s CAR-T cell therapy, Azer-cel.Initially, NeoImmuneTech will supply NT-17 at no
"JLK has many strategies in place to enter the U.S. market. In particular, we plan to provide differentiated value in the U.S. healthcare market by providing accurate and rapid diagnosis methods using artificial intelligence (AI) technology in the field of stroke diagnosis."JLK CEO Kim Dong-min shar
SK Bioscience and Sanofi have started the process of submitting a phase 3 Investigational New Drug (IND) to the U.S. FDA for their jointly developed 21-valent pneumococcal protein conjugate vaccine candidate, GBP410 (Sanofi's project name: SP0202), to proceed to clinical trials, the Korean vaccinema
HLB’s transfer listing from the tech-heavy Kosdaq to the main bourse Kospi market has received the green light. HLB said Friday that ISS (International Shareholder Services), a global proxy advisory firm, has issued a favorable opinion on its enhanced stock market listing to investment management fi
Many third-generation executives of family-run conglomerates are assuming key roles in their group’s biopharmaceutical affiliates.SK biopharmaceuticals said Thursday it promoted Chey Yoon-jung, who had led the company’s strategic investment team, to head its business development headquarters. Chey i
Bridge Biotherapeutics, a Kosdaq-listed drug development company, said Wednesday that it has received confirmation from the FDA to go ahead with a clinical trial of BBT-301, a candidate for the treatment of idiopathic pulmonary fibrosis (IPF).The 505(b)(2) application, part of the FDA's new drug app
Y-Biologics held a ceremony to celebrate its listing on the Kosdaq market at the Korea Exchange on Tuesday.Y-Biologics conducted a demand forecast for institutional investors from Nov. 10 to 16 and finalized the initial public offering price of 9,000 won ($6.85). A total of 911 institutions particip
MedPacto, a Kosdaq-listed biotech company, said Monday that MP2021, its new drug candidate for treating bone diseases, has been selected for the National New Drug Development Project.MP2021 was finally included in the third round of support for non-clinical development by the Korea Drug Development
Samsung Bioepis and Intocell have announced the signing of a joint research agreement for the development and validation of candidate materials in the field of antibody-drug conjugates (ADC).Founded in 2015, Intocell is a Korean company focused on the development of ADC linker-drug technologies. The
Celltrion said it confirmed the efficacy of CT-P42, a biosimilar referencing Eylea (ingredient: aflibercept), in a phase 3 study. The company presented the trial results during the FLORetina–ICOOR 2023 conference.Eylea is a blockbuster ophthalmic drug developed by Regeneron and treats wet age-relate
Kolon Life Science said Friday that its patent for recombinant vaccinia virus and use thereof, a platform technology for anticancer therapeutics, was recently granted recognition by the European Patent Office (EPO).To overcome the limitations of the vaccinia virus, which kills tumors but also kills
The Ministry of Food and Drug Safety (MFDS) has expressed its position on revoking the Good Manufacturing Practices (GMP) certificate for Hutecs Korea Pharmaceutical, urging the industry to remain vigilant against intentional GMP violations."GMP violations are not a problem unique to Korea. There ar
Celltrion Healthcare is set to launch Zymfentra, also known as Remsima SC internationally, the sole subcutaneous formulation of infliximab for autoimmune diseases, in the U.S. on February 29, 2024.The launch comes nearly four months after the drug received marketing authorization from the FDA on Oct
Cellid, a developer of cancer immunotherapy and Covid-19 vaccines, said Tuesday that it has begun dosing subjects in a phase 3 clinical trial of its Covid-19 Omicron-specific vaccine, Adcld-cov19-1 OMI, at Korea University Ansan Hospital in Gyeonggi Province and Dong-A University Hospital in Busan.T
NgeneBio, a Kosdaq-listed biotech firm, said Tuesday that it has obtained marketing authorization for Hemeaccutest, a blood cancer precision diagnostic panel based on next-generation sequencing (NGS) technology, from the Thai Food and Drug Administration (TFDA).Hemeaccutest, utilizing NGS, can ident
Samsung Biologics said Tuesday that it has signed one new and four expanded contract manufacturing organization (CMO) deals, bringing its annual order intake to 3.48 trillion won ($2.7 billion) for the first time since its founding. This largely exceeds last year's order intake of 1.78 trillion won.
Y-Biologics, a novel antibody-drug developer, reported an oversubscription of 834.9 times the offered shares in its public offering.Y-Biologics carried out the initial public offering (IPO) for general subscribers on Thursday and Friday. For 375,000 shares allotted for retail investors, 25 percent o
Bio Investments Group AG, a Swiss-based investment company, strongly denied media reports that the company and its CEO, Sam Mchour, were involved in the planned acquisition of Boryung Biopharma, a biopharma unit of Boryung Group based in Korea. Some media outlets reported Thursday that PCL, an in vi
Celltrion said it recently submitted a marketing authorization application for CT-P42, an Eylea (aflibercept) biosimilar, to the European Medicines Agency (EMA).The application is for wet age-related macular degeneration (wAMD), cystoid retinal vein occlusive (CRVO-BRVO) macular edema, diabetic macu
Lemonex, a drug delivery platform biotechnology company, said Thursday that it has signed a memorandum of understanding (MOU) with Health Innovation East, an organization under the National Health Service (NHS) in the U.K., to develop and commercialize an mRNA-DegradaBALL vaccine using Lemonex's dru